
McDavid Stilwell appointed as CFO of CPTx
Ella Day | April 28, 2025 | Appointment | Research and Development | CPTx, Immunology, Oncology, appointment, cfo, therapeutics
CPTx, a German biotech company focused on single-stranded DNA therapeutics, has announced the appointment of McDavid Stilwell as chief financial officer (CFO). Stilwell will support the development of its two leading programmes towards commercialisation.
Stillwell will be responsible for CPTx’s financial strategy and operations, investor relations and business development functions. This should advance the company’s ambition to clinically develop and commercialise leading assets, in vivo CAR-T therapy for blood cancer and autoimmune disease and its self-delivering gene carrier.
The new CFO brings over 25 years of experience in finance, corporate development, investor relations and communications to CPTx. He previously served as CFO at Coherus Biosciences, has held leadership roles at Sangamo and Orexigen.
Hendrik Dietz, CEO of CPTx commented: “With his [Stilwell’s] deep biopharma finance, corporate strategy and investor relations experience, he boosts our executive team capabilities as we advance development of our lead programmes toward clinical development and potential partnerships.”
“I am excited to help lead the CPTx team to apply their expertise in single-stranded DNA technology to develop in vivo genetic medicines that overcome delivery and access challenges of current cell and gene therapies,” added Stilwell.
Ella Day
28/4/25
Related Content

Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …






